Minimally Invasive Surgery Benefits Pancreatoduodenectomy Patients Post-Neoadjuvant Treatment

This study delves into the impact of surgical approach on the 30-day outcomes of pancreatic cancer patients after neoadjuvant treatment (NAT). Researchers compared minimally invasive pancreatoduodenectomy (MIPD) and open pancreatoduodenectomy (OPD) within NAT groups. Among the 5,588 patients analyzed, MIPD after neoadjuvant chemotherapy alone resulted in lower complication rates, shorter hospital stays, and fewer complications compared to OPD. These findings suggest that MIPD is a safe and feasible option for patients who undergo NAT, potentially improving their postoperative recovery.